Skip to content
OnKommon
OnKommon AVATAR

Stage 05 · Integrate and review

One integrated report. Two kinds of evidence.

AVATAR brings molecular interpretation and biological drug-screening findings together in one integrated report for multidisciplinary review.
  1. 01Interpret
  2. 02Model
  3. 03Screen
  4. 04Observe
  5. 05Review

Integrated report

What the report contains

Every element is labelled with the kind of evidence it represents.
  • Computational observation

    Molecular findings

    Relevant drivers, response biomarkers, supporting evidence and open questions from the Interpreter.

  • Experimental model observation

    Screening observations

    Responses recorded in the engineered model under the conditions tested.

  • For oncologist assessment

    Limitations

    What the model represents, what it does not, and the experimental constraints.

  • Investigational candidate

    Considerations for assessment

    Hypotheses and questions for multidisciplinary review and further research.

From streams to review

How the report is reviewed

OnKommon Interpreter

Computational
  1. 01Tumour genome
  2. 02Variant analysis
  3. 03Evidence interpretation
  4. 04Molecular findings

What does the genomic evidence show, and how strong is it?

AVATAR Discovery Process

Experimental
  1. 01Selected tumour mutations
  2. 02Engineered fruit-fly model
  3. 03Drug screening
  4. 04Experimental observations

What responses were seen when candidate drugs were screened in the model?

Integrated report

Molecular findings, screening observations, limitations and considerations for assessment.

KPCIRC Molecular Tumour Board

Reviews findings, interpretation, clinical context and therapeutic implications.

Treating oncologist

Finalises and signs the report. Retains ultimate clinical ownership of treatment decisions.

Computation provides molecular evidence; screening provides experimental evidence; the MTB reviews; the treating oncologist owns the decision.

The treating oncologist owns every decision. Every AVATAR integrated report is reviewed by KPCIRC's Molecular Tumour Board, then finalised and signed by the treating oncologist.

KPCIRC sign-off process

Stage summary

Integration and review

05

Review · KPCIRC MTB · Treating oncologist

Integration and clinician-led review

Investigational candidateFor oncologist assessment
What happens
Molecular interpretation and biological screening observations are brought together in one integrated report. KPCIRC's Molecular Tumour Board reviews it, and the treating oncologist finalises and signs it.
Inputs
Both evidence streams — molecular and experimental.
Intended output
An integrated report: molecular findings, screening observations and considerations for assessment.
What it establishes
A structured basis for multidisciplinary discussion and further research.
Why it matters
The treating oncologist receives one biological investigational plan, signed and owned by them.

Understand what the outputs can establish.

EvidenceDiscuss a collaboration

Continue the journey

For doctors

Superpowers for the treating oncologist.

→